Lexeo Net Debt from 2010 to 2026

LXEO Stock   6.31  0.02  0.32%   
Lexeo Therapeutics Net Debt yearly trend continues to be very stable with very little volatility. Net Debt is likely to drop to about -30.3 M. Net Debt is the total debt of Lexeo Therapeutics Common minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals
 
Net Debt  
First Reported
2010-12-31
Previous Quarter
-28.9 M
Current Value
-30.3 M
Quarterly Volatility
31.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Lexeo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexeo Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9 M or Depreciation And Amortization of 2.4 M, as well as many indicators such as Price To Sales Ratio of 377, Dividend Yield of 0.0 or PTB Ratio of 1.69. Lexeo financial statements analysis is a perfect complement when working with Lexeo Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Lexeo Stock
Check out the analysis of Lexeo Therapeutics Correlation against competitors.
Evaluating Lexeo Therapeutics's Net Debt across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Lexeo Therapeutics Common's fundamental strength.

Latest Lexeo Therapeutics' Net Debt Growth Pattern

Below is the plot of the Net Debt of Lexeo Therapeutics Common over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Lexeo Therapeutics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexeo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Debt10 Years Trend
Slightly volatile
   Net Debt   
       Timeline  

Lexeo Net Debt Regression Statistics

Arithmetic Mean(42,169,763)
Coefficient Of Variation(75.54)
Mean Deviation21,533,142
Median(29,373,209)
Standard Deviation31,856,076
Sample Variance1014.8T
Range110.8M
R-Value(0.33)
Mean Square Error967.8T
R-Squared0.11
Significance0.20
Slope(2,053,186)
Total Sum of Squares16237T

Lexeo Net Debt History

2026-30.3 M
2025-28.9 M
2024-25.1 M
2023-109.8 M
2022-63.9 M
2021-135.9 M

Other Fundumenentals of Lexeo Therapeutics Common

Lexeo Therapeutics Net Debt component correlations

About Lexeo Therapeutics Financial Statements

Lexeo Therapeutics investors utilize fundamental indicators, such as Net Debt, to predict how Lexeo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Debt-28.9 M-30.3 M
Net Debt To EBITDA 0.30  0.28 

Pair Trading with Lexeo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lexeo Stock

  0.66OSE OSE Pharma SAPairCorr

Moving against Lexeo Stock

  0.86C1 CytomX TherapeuticsPairCorr
  0.778VP1 AVRICORE HEALTH INCPairCorr
  0.72VALN Valneva SE ADRPairCorr
  0.72DRTS Alpha Tau MedicalPairCorr
  0.71DNTH Dianthus TherapeuticsPairCorr
The ability to find closely correlated positions to Lexeo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics Common to buy it.
The correlation of Lexeo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lexeo Therapeutics Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexeo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexeo Therapeutics Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexeo Therapeutics Common Stock:
Check out the analysis of Lexeo Therapeutics Correlation against competitors.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Will Biotechnology sector continue expanding? Could Lexeo diversify its offerings? Factors like these will boost the valuation of Lexeo Therapeutics. Expected growth trajectory for Lexeo significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lexeo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.50)
Return On Assets
(0.45)
Return On Equity
(0.81)
Investors evaluate Lexeo Therapeutics Common using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Lexeo Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Lexeo Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Lexeo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lexeo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Lexeo Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.